Stockscreener 앱 받기
162.00
1.22%
1.95
시간 외 거래:
162.81
0.81
+0.50%
전일 마감가:
$160.05
열려 있는:
$157.77
하루 거래량:
212.03K
Relative Volume:
0.44
시가총액:
$9.88B
수익:
$393.98M
순이익/손실:
$-367.45M
주가수익비율:
-25.74
EPS:
-6.293
순현금흐름:
$-460.07M
1주 성능:
+2.79%
1개월 성능:
+2.44%
6개월 성능:
+24.80%
1년 성능:
+25.15%
1일 변동 폭
$153.49
$162.12
1주일 범위
$153.49
$162.38
52주 변동 폭
$111.09
$183.00
Ascendis Pharma A S Adr Stock (ASND) Company Profile
ASND을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S Adr
|
162.00 | 9.53B | 393.98M | -367.45M | -460.07M | -6.293 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Ascendis Pharma A S Adr Stock (ASND) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-04-16 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-07 | 개시 | UBS | Buy |
| 2024-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-06-25 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-05-31 | 개시 | Stifel | Buy |
| 2023-12-20 | 개시 | Jefferies | Buy |
| 2023-06-14 | 재개 | Credit Suisse | Neutral |
| 2023-04-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-04-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-03 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-10-20 | 개시 | Goldman | Buy |
| 2022-08-30 | 재개 | Berenberg | Buy |
| 2022-03-28 | 재개 | Wedbush | Outperform |
| 2022-03-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-06 | 개시 | Cowen | Market Perform |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-10-20 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-30 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-03-11 | 재개 | Stifel | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-03-20 | 개시 | Oppenheimer | Outperform |
| 2019-10-11 | 개시 | Morgan Stanley | Overweight |
| 2019-03-25 | 개시 | Evercore ISI | Outperform |
| 2019-01-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-01-24 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-06-26 | 개시 | Stifel | Buy |
| 2018-04-02 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-05-11 | 개시 | JP Morgan | Overweight |
| 2017-03-09 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-02-09 | 개시 | Credit Suisse | Outperform |
| 2016-09-26 | 개시 | Wedbush | Outperform |
모두보기
Ascendis Pharma A S Adr 주식(ASND)의 최신 뉴스
Ascendis Pharma’s SWOT analysis: strong product pipeline drives stock potential - Investing.com
Ascendis Pharma grants new employee warrants - Investing.com
Ascendis Pharma reports growth in achondroplasia trial By Investing.com - Investing.com India
Ascendis Pharma reports growth in achondroplasia trial - Investing.com
Cantor maintains $200 target on Ascendis Pharma stock By Investing.com - Investing.com India
European Stocks Show Mixed Results With Novo Nordisk Leading Gains - Finimize
In the Green: Ascendis Pharma A/S ADR (ASND) Closes at 160.99, Up/Down -1.14 from Previous Day - DWinneX
Ascendis Pharma stock target raised to $245 by JPMorgan - Investing.com
Ascendis Pharma A/S ADR (ASND) stock on the rise: An overview - uspostnews.com
Ascendis Pharma AS earnings missed by €0.11, revenue topped estimates - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
RBC Capital sets $205 target on Ascendis Pharma stock - Investing.com
Banco Macro ADR Earns Relative Strength Rating Upgrade - inkl
Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory (ASND) - Seeking Alpha
Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily
Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Jump To 87 - Investor's Business Daily
European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading - TradingView
UBS maintains Ascendis Pharma stock Buy rating, $196 target - Investing.com
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - TradingView
Ascendis Pharma ADR Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily
European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Tread Water in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Lower Wednesday - TradingView
Ascendis Pharma A/S Sponsored ADR to Host Earnings Call - ACCESS Newswire
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up Slightly for Week - TradingView
Ascendis Pharma at TD Cowen Conference: Strategic Growth in Rare Diseases - Investing.com
Ascendis Pharma's SWOT analysis: stock outlook amid Yorvipath success, Skytrofa challenges - Investing.com
Cantor Fitzgerald lifts Ascendis Pharma target to $200, maintains Overweight - Investing.com
Why Is BioMarin Stock Trading Higher On Thursday? - Benzinga
Stocks To Watch: Kontoor Brands Sees RS Rating Rise To 84 - Inkl
Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Rise To 82 - Investor's Business Daily
Stocks To Watch: Pony AI ADR Sees RS Rating Jump To 92 - Inkl
Ascendis Pharma's SWOT analysis: promising pipeline fuels stock potential - Investing.com
ASND’s price-to-free cash flow ratio: A closer look at its relevance - US Post News
Earnings call transcript: Ascendis Pharma Q4 2024 sees revenue rise - Investing.com
Ascendis Pharma launches $25 million share buyback - Investing.com
European Equities Traded in the US as American Depositary Receipts Tread Water in Wednesday Trading - TradingView
Cantor Fitzgerald maintains Ascendis Pharma Overweight rating By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains Ascendis Pharma Overweight rating - Investing.com
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading - MSN
JPMorgan raises Ascendis Pharma target to $167, keeps Overweight - Investing.com
Ascendis Pharma A/S (ASND) Expected to Announce Earnings on Wednesday - Defense World
Goldman Sachs retains Buy on Ascendis Pharma shares, cites legal action - Investing.com
BioMarin sues Ascendis Pharma over patent infringement - Investing.com
Ascendis Pharma stock falls on missed Skytrofa revenue forecast - Investing.com
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading - MSN
European Equities Traded in US as American Depositary Receipts Surge on Monday - MSN
UBS starts Ascendis Pharma stock at Buy, optimistic on upcoming launches - Investing.com
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Rise in Monday Trading - MSN
Ascendis Pharma A S Adr (ASND) 재무 분석
매출
순이익
현금흐름
주당 순 이익
17.27%
1.06%
자본화:
|
볼륨(24시간):